Cervical cancer is the number one cancer killer of women in sub-Saharan Africa (SSA), with roughly 100,000 women diagnosed annually; of these women, about 62% will die from the disease. Women living with HIV (WLHIV) are up to five times more likely to develop persistent precancerous lesions and progress to cervical cancer, often with more aggressive form and higher mortality.

Launched in May 2018 to address this challenge, Go Further is an innovative public-private partnership between the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the George W. Bush Institute, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and Merck. The partnership collaborates closely with governments to strategize on ways to provide services for women from prevention through the cancer journey. Go Further began working in eight countries (Botswana, Eswatini, Lesotho, Malawi, Mozambique, Namibia, Zambia, and Zimbabwe), and will expand services to four additional countries (Ethiopia, Kenya, Tanzania, Uganda) in fiscal year (FY) 2021. The objectives are to screen all WLHIV on ART between the ages of 25 and 49 for cervical cancer, and to treat pre-invasive cervical cancer lesions to prevent progression to cervical cancer.

## Zimbabwe Program Highlights

<table>
<thead>
<tr>
<th></th>
<th>Funding Amount</th>
<th>WLHIV on Treatment*</th>
<th>Cervical Cancer Screening Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY19</td>
<td>$4,900,000</td>
<td>200,000</td>
<td>100,000</td>
</tr>
<tr>
<td>FY20</td>
<td>$5,482,750</td>
<td>410,866</td>
<td>244,620</td>
</tr>
<tr>
<td>FY21</td>
<td>$4,511,918</td>
<td>392,805</td>
<td>218,412</td>
</tr>
</tbody>
</table>

* For FY19, this is the number of women aged 30+ estimated to be on treatment; otherwise, this is women aged 25–49 on treatment at the end of FYs 18 and 19, respectively. (Source: PEPFAR Panorama Spotlight)

---

### Country Context

#### Zimbabwe: Cervical cancer screenings and positives (precancerous lesions or suspected invasive cervical cancer), FY18-FY19

- **Total Population (July 2020 est.)** (World Factbook): 14,546,314
- **Women Aged 15-49 HIV Prevalence Rate (UNAIDS 2019):** 15.4%
- **Age-standardized Incidence Rate (per 100,000) of Cervical Cancer Cases Attributable to HPV (Estimates for 2018) (HPV Information Center):** 62.3
- **Total # of Women (All Ages) On ART (PEPFAR, FY20 Q2):** 591,463
Strategic Direction for FY21

- Since 2014, the Ministry of Health and Child Care (MoHCC) has been rapidly scaling up screening of cervical cancer using visual inspection with acetic acid and cervicography (VIAC) and over 100 VIAC sites have been set up at district, provincial and central levels countrywide.

- Procurement of equipment and commodities is ongoing.

- There has been also recruitment and training of VIAC nurses to work full time in the VIAC clinics. This activity also spearheaded the formation of a cervical cancer monitoring and evaluation technical working group.

- The national VIAC register and the master MoHCC monthly return were revised to incorporate the PEPFAR VIAC indicators.

In FY20: 74,344 screenings were done, representing 30% of the FY20 target, and 49% of women who screened positive for precancerous lesions were treated.

Since FY19: 1,730 women have screened positive for suspected invasive cervical cancer. Of the 141,599 screenings, 110,928 (78.3%) were first time screenings, 1,075 (0.8%) were follow-up screenings, and 29,596 (20.9%) were re-screens.

Implementing Partners (FY20)

- University of Washington
- Zimbabwe Association of Church Related Hospital
- Population Services International
- Organization for Public Health Interventions and Development

# of Cervical Cancer Screenings

<table>
<thead>
<tr>
<th></th>
<th>FY19Q2</th>
<th>FY19Q4</th>
<th>FY20Q2</th>
</tr>
</thead>
<tbody>
<tr>
<td>20,854</td>
<td>46,401</td>
<td>74,344</td>
<td></td>
</tr>
</tbody>
</table>

Cervical Cancer Cascade

- 141,599 screenings
- 10,041 screened positive for precancerous lesions
- 5,106 treated